search
Back to results

Efficacy and Safety of Dapagliflozin in Combination With Glimepiride (a Sulphonylurea) in Type 2 Diabetes Patients

Primary Purpose

Type 2 Diabetes

Status
Completed
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
dapagliflozin
Glimepiride
metformin hydrochloride
pioglitazone hydrochloride
Rosiglitazone
Sponsored by
AstraZeneca
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Type 2 Diabetes focused on measuring Dapagliflozin, efficacy, safety, sulphonylurea, Type 2 diabetes

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Type 2 Diabetes
  • Treatment with a stable sulphonylurea monotherapy dose that is at least half the maximal recommended dose for a minimum of 8 weeks prior to study
  • Inadequate glycaemic control, defined as A1C ≥ 7.0 % and ≤ 10%

Exclusion Criteria:

  • Type 1 Diabetes
  • Hepatic (liver) impairment
  • Renal (kidney) failure or dysfunction

Sites / Locations

  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Experimental

Experimental

Placebo Comparator

Arm Label

1

2

3

4

Arm Description

dapagliflozin 2.5mg + Glimepiride

dapagliflozin 5mg + Glimepiride

dapagliflozin 10mg + Glimepiride

Placebo + Glimepiride

Outcomes

Primary Outcome Measures

Adjusted Mean Change in HbA1c Levels
To assess the efficacy of dapagliflozin compared to placebo as add-on therapy to glimepiride in improving glycemic control in participants with type 2 diabetes, as determined by the change in HbA1C levels from baseline to the end of the 24-week double-blind treatment period.

Secondary Outcome Measures

Adjusted Mean Change in Body Weight
To show that dapagliflozin plus glimepiride results in greater reduction in body weight or less weight gain after 24 weeks of treatment when compared to placebo plus glimepiride.
Adjusted Mean Change in 2-h Post-challenge Plasma Glucose Rise
To show that dapagliflozin plus glimepiride results in greater reductions in the 2-h post-challenge plasma glucose rise as a response to an oral glucose tolerance test (OGTT) from baseline to Week 24.
Proportion of Participants Achieving Glycemic Response Defined as HbA1c <7%
To show that dapagliflozin plus glimepiride results in a larger proportion of participants achieving a therapeutic glycemic response, defined as HbA1c < 7% after 24 weeks of treatment, compared to placebo plus glimepiride.
Adjusted Mean Change in Body Weight for Participants With Baseline Body Mass Index (BMI)≥27 kg/m2
To show that dapagliflozin plus glimepiride results in greater reductions in body weight or less weight gain in participants with baseline BMI ≥27 kg/m2 after 24 weeks of treatment when compared to placebo plus glimepiride.
Adjusted Mean Change in Fasting Plasma Glucose (FPG)
To show that dapagliflozin plus glimepiride leads to greater reductions in FPG after 24 weeks of treatment compared to placebo plus glimepiride.

Full Information

First Posted
May 16, 2008
Last Updated
August 9, 2013
Sponsor
AstraZeneca
Collaborators
Bristol-Myers Squibb
search

1. Study Identification

Unique Protocol Identification Number
NCT00680745
Brief Title
Efficacy and Safety of Dapagliflozin in Combination With Glimepiride (a Sulphonylurea) in Type 2 Diabetes Patients
Official Title
A 24-Week,Int.,Rand.,Double-blind,Parallel-group,Multi-centre, Plac.-Controlled Phase III Study With a 24-Wk Ext.Per.to Eval.the Efficacy and Safety of Dapagliflozin in Comb.With Glimepiride (a Sulphonylurea) in Subjects With Type2 Diab.Who Have Inadeq. Glycaemic Control on Glimepiride Therapy Alone
Study Type
Interventional

2. Study Status

Record Verification Date
August 2013
Overall Recruitment Status
Completed
Study Start Date
April 2008 (undefined)
Primary Completion Date
November 2009 (Actual)
Study Completion Date
May 2010 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
AstraZeneca
Collaborators
Bristol-Myers Squibb

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
This study is being carried out to see if dapagliflozin in addition to glimepiride (sulphonylurea) is effective and safe in treating patients with type 2 diabetes when compared to glimepiride alone.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes
Keywords
Dapagliflozin, efficacy, safety, sulphonylurea, Type 2 diabetes

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
597 (Actual)

8. Arms, Groups, and Interventions

Arm Title
1
Arm Type
Experimental
Arm Description
dapagliflozin 2.5mg + Glimepiride
Arm Title
2
Arm Type
Experimental
Arm Description
dapagliflozin 5mg + Glimepiride
Arm Title
3
Arm Type
Experimental
Arm Description
dapagliflozin 10mg + Glimepiride
Arm Title
4
Arm Type
Placebo Comparator
Arm Description
Placebo + Glimepiride
Intervention Type
Drug
Intervention Name(s)
dapagliflozin
Intervention Description
tablet oral 2.5, 5, or 10 mg total daily dose once daily 48 weeks
Intervention Type
Drug
Intervention Name(s)
Glimepiride
Other Intervention Name(s)
Amaryl
Intervention Description
tablet oral 2.5, 5, or 10 mg total daily dose once daily 48 weeks
Intervention Type
Drug
Intervention Name(s)
metformin hydrochloride
Other Intervention Name(s)
Glucophage
Intervention Description
rescue medication oral dosing in accordance with the manufacturer's recommendations and clinical practice
Intervention Type
Drug
Intervention Name(s)
pioglitazone hydrochloride
Other Intervention Name(s)
Actos
Intervention Description
rescue medication oral dosing in accordance with the manufacturer's recommendations and clinical practice
Intervention Type
Drug
Intervention Name(s)
Rosiglitazone
Other Intervention Name(s)
Avandia
Intervention Description
rescue medication oral dosing in accordance with the manufacturer's recommendations and clinical practice
Primary Outcome Measure Information:
Title
Adjusted Mean Change in HbA1c Levels
Description
To assess the efficacy of dapagliflozin compared to placebo as add-on therapy to glimepiride in improving glycemic control in participants with type 2 diabetes, as determined by the change in HbA1C levels from baseline to the end of the 24-week double-blind treatment period.
Time Frame
Baseline to Week 24
Secondary Outcome Measure Information:
Title
Adjusted Mean Change in Body Weight
Description
To show that dapagliflozin plus glimepiride results in greater reduction in body weight or less weight gain after 24 weeks of treatment when compared to placebo plus glimepiride.
Time Frame
Baseline to Week 24
Title
Adjusted Mean Change in 2-h Post-challenge Plasma Glucose Rise
Description
To show that dapagliflozin plus glimepiride results in greater reductions in the 2-h post-challenge plasma glucose rise as a response to an oral glucose tolerance test (OGTT) from baseline to Week 24.
Time Frame
Baseline to Week 24
Title
Proportion of Participants Achieving Glycemic Response Defined as HbA1c <7%
Description
To show that dapagliflozin plus glimepiride results in a larger proportion of participants achieving a therapeutic glycemic response, defined as HbA1c < 7% after 24 weeks of treatment, compared to placebo plus glimepiride.
Time Frame
At Week 24
Title
Adjusted Mean Change in Body Weight for Participants With Baseline Body Mass Index (BMI)≥27 kg/m2
Description
To show that dapagliflozin plus glimepiride results in greater reductions in body weight or less weight gain in participants with baseline BMI ≥27 kg/m2 after 24 weeks of treatment when compared to placebo plus glimepiride.
Time Frame
Baseline to Week 24
Title
Adjusted Mean Change in Fasting Plasma Glucose (FPG)
Description
To show that dapagliflozin plus glimepiride leads to greater reductions in FPG after 24 weeks of treatment compared to placebo plus glimepiride.
Time Frame
Baseline to Week 24

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Type 2 Diabetes Treatment with a stable sulphonylurea monotherapy dose that is at least half the maximal recommended dose for a minimum of 8 weeks prior to study Inadequate glycaemic control, defined as A1C ≥ 7.0 % and ≤ 10% Exclusion Criteria: Type 1 Diabetes Hepatic (liver) impairment Renal (kidney) failure or dysfunction
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Krzysztof Strojek, Prof. Dr.
Organizational Affiliation
Silesian Medical University3-Maja 13/15, 41-800 Zabrze; Poland
Official's Role
Principal Investigator
Facility Information:
Facility Name
Research Site
City
Blansko
Country
Czech Republic
Facility Name
Research Site
City
Breclav
Country
Czech Republic
Facility Name
Research Site
City
Bruntal
Country
Czech Republic
Facility Name
Research Site
City
Hodonin
Country
Czech Republic
Facility Name
Research Site
City
Ostrava - Belsky Les
Country
Czech Republic
Facility Name
Research Site
City
Plzen
Country
Czech Republic
Facility Name
Research Site
City
Praha 1
Country
Czech Republic
Facility Name
Research Site
City
Pribram Viii
Country
Czech Republic
Facility Name
Research Site
City
Rakovnik
Country
Czech Republic
Facility Name
Research Site
City
Semily
Country
Czech Republic
Facility Name
Research Site
City
Balatonfured
Country
Hungary
Facility Name
Research Site
City
Bekescsaba
Country
Hungary
Facility Name
Research Site
City
Budapest
Country
Hungary
Facility Name
Research Site
City
Csongrad
Country
Hungary
Facility Name
Research Site
City
Eger
Country
Hungary
Facility Name
Research Site
City
Gyongyos
Country
Hungary
Facility Name
Research Site
City
Kecskemet
Country
Hungary
Facility Name
Research Site
City
Mako
Country
Hungary
Facility Name
Research Site
City
Miskolc
Country
Hungary
Facility Name
Research Site
City
Mosonmagyarovar
Country
Hungary
Facility Name
Research Site
City
Siofok
Country
Hungary
Facility Name
Research Site
City
Szentes
Country
Hungary
Facility Name
Research Site
City
TAT
Country
Hungary
Facility Name
Research Site
City
Zalaegerszeg
Country
Hungary
Facility Name
Research Site
City
Jeonju
State/Province
Chonbuk
Country
Korea, Republic of
Facility Name
Research Site
City
Wonju
State/Province
Kangwon-do
Country
Korea, Republic of
Facility Name
Research Site
City
Suwon
State/Province
Kyunggi-do
Country
Korea, Republic of
Facility Name
Research Site
City
Bucheon
Country
Korea, Republic of
Facility Name
Research Site
City
Incheon
Country
Korea, Republic of
Facility Name
Research Site
City
Seongnam
Country
Korea, Republic of
Facility Name
Research Site
City
Seoul
Country
Korea, Republic of
Facility Name
Research Site
City
Uljeongbu
Country
Korea, Republic of
Facility Name
Research Site
City
Cebu City
Country
Philippines
Facility Name
Research Site
City
Manila
Country
Philippines
Facility Name
Research Site
City
Marikina City
Country
Philippines
Facility Name
Research Site
City
Pasig City
Country
Philippines
Facility Name
Research Site
City
Bielsko - Biala
Country
Poland
Facility Name
Research Site
City
Bydgoszcz
Country
Poland
Facility Name
Research Site
City
Chojnice
Country
Poland
Facility Name
Research Site
City
Chrzanow
Country
Poland
Facility Name
Research Site
City
Ciechocinek
Country
Poland
Facility Name
Research Site
City
Czechowice-Dziedzice
Country
Poland
Facility Name
Research Site
City
Elblag
Country
Poland
Facility Name
Research Site
City
Gdansk
Country
Poland
Facility Name
Research Site
City
Gniewkowo
Country
Poland
Facility Name
Research Site
City
Grudziadz
Country
Poland
Facility Name
Research Site
City
Ilawa
Country
Poland
Facility Name
Research Site
City
Krakow
Country
Poland
Facility Name
Research Site
City
Mragowo
Country
Poland
Facility Name
Research Site
City
Plock
Country
Poland
Facility Name
Research Site
City
Poznan
Country
Poland
Facility Name
Research Site
City
Ruda Slaska
Country
Poland
Facility Name
Research Site
City
Sopot
Country
Poland
Facility Name
Research Site
City
Torun
Country
Poland
Facility Name
Research Site
City
Wroclaw
Country
Poland
Facility Name
Research Site
City
Zabrze
Country
Poland
Facility Name
Research Site
City
Zielona Gora
Country
Poland
Facility Name
Research Site
City
Zory
Country
Poland
Facility Name
Research Site
City
Bangkok
Country
Thailand
Facility Name
Research Site
City
Chiang Mai
Country
Thailand
Facility Name
Research Site
City
Dnipropetrov'sk
Country
Ukraine
Facility Name
Research Site
City
Donetsk
Country
Ukraine
Facility Name
Research Site
City
Kharkiv
Country
Ukraine
Facility Name
Research Site
City
Kiev
Country
Ukraine
Facility Name
Research Site
City
Vinnytsia
Country
Ukraine
Facility Name
Research Site
City
Zaporozhye
Country
Ukraine

12. IPD Sharing Statement

Citations:
PubMed Identifier
33368935
Citation
Shah M, Stolbov L, Yakovleva T, Tang W, Sokolov V, Penland RC, Boulton D, Parkinson J. A model-based approach to investigating the relationship between glucose-insulin dynamics and dapagliflozin treatment effect in patients with type 2 diabetes. Diabetes Obes Metab. 2021 Apr;23(4):991-1000. doi: 10.1111/dom.14305. Epub 2021 Jan 25.
Results Reference
derived
PubMed Identifier
23529567
Citation
Strojek K, Yoon KH, Hruba V, Elze M, Langkilde AM, Parikh S. [Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride]. Dtsch Med Wochenschr. 2013 Apr;138 Suppl 1:S16-26. doi: 10.1055/s-0032-1305277. Epub 2013 Mar 25. German.
Results Reference
derived
PubMed Identifier
21672123
Citation
Strojek K, Yoon KH, Hruba V, Elze M, Langkilde AM, Parikh S. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2011 Oct;13(10):928-38. doi: 10.1111/j.1463-1326.2011.01434.x.
Results Reference
derived

Learn more about this trial

Efficacy and Safety of Dapagliflozin in Combination With Glimepiride (a Sulphonylurea) in Type 2 Diabetes Patients

We'll reach out to this number within 24 hrs